Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Content Team by Content Team
30th January 2019
in Drug Development, Manufacturing, Market Moves, Packaging & Logistic
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Aldeyra Therapeutics, Inc. , a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company.

The acquisition adds to Aldeyra’s pipeline a Phase 3-ready product candidate (ADX-2191, intravitreal methotrexate) for the treatment of proliferative vitreoretinopathy (PVR), a serious sight-threatening condition with no approved treatment. ADX-2191 has received Orphan Drug Designation from the U.S. Food and Drug Administration.

PVR, a serious inflammatory condition that can cause permanent vision loss, affects up to 10% of patients undergoing surgery for retinal detachment, and 50% or more of patients undergoing retina surgery following open globe injury. ADX-2191 is an innovative therapeutic option discovered by Dr. Dean Eliott, the Stelios Evangelos Gragoudas Associate Professor of Ophthalmology at Harvard Medical School and the Director of the Retina Service at Massachusetts Eye and Ear Infirmary (MEEI). ADX-2191 was co-developed by Dr. Eliott and Dr. Tomasz Stryjewski, also a retinal surgeon at MEEI.

“The acquisition of Helio Vision is highly complementary to Aldeyra’s focus on novel therapeutic approaches for immune-mediated diseases and broadens our late-stage pipeline,” stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Helio Vision’s unique approach is at the cross-hairs of our areas of expertise, leveraging an immunological mechanism that diminishes inflammation and cell proliferation, an orphan indication addressing a significant unmet medical need, the potential applicability to a variety of other diseases, and a Phase 3-ready retinal program that represents another important catalyst in our development pipeline.”

“We are thrilled to be working with Aldeyra to develop a novel treatment approach for PVR, a debilitating disease for which there is no approved therapy,” stated Josef H. von Rickenbach, co-founder, President and CEO of Helio Vision. “Aldeyra’s proven track record of development success across a number of clinical programs bodes well for the advancement of ADX-2191.”

Under the terms of the agreement, Aldeyra has acquired Helio Vision for an upfront payment of approximately $10 million in common stock, subject to a six-month lock-up period, and an additional $2.5 million payment in common stock two years from the date of closing, subject to certain terms and conditions of the agreement. Helio Vision shareholders will also be eligible to receive up to an additional $12.5 million in Aldeyra stock upon achievement of certain regulatory milestones. Dr. Eliott and the other co-founders of Helio Vision will continue to work with Aldeyra on ADX-2191 as consultants under the terms of the acquisition.

The acquisition of Helio Vision and the near-term development of ADX-2191 has no impact on Aldeyra’s previous financial guidance. An adaptive Phase 3 clinical program for ADX-2191 in PVR is expected to initiate in 2019, with results expected in 2020.

About Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy (PVR) is a rare inflammatory fibroproliferative disorder that leads to severe retinal scarring and blindness, and is the leading cause of failure of retinal reattachment surgery. Over 50% of PVR cases result in severe uncorrectable vision loss, and 76% of PVR patients suffer from at least moderate uncorrectable vision loss. PVR complicates up to 10% of surgeries for retinal detachment and 50% or more of surgeries for open globe injury. There is currently no approved therapy for the treatment of PVR.

About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal disease, metabolic disease, and cancer.

Previous Post

CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor BLU-554 (CS3008)

Next Post

Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology

Related Posts

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet
Manufacturing

Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet

20th February 2019
Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Clinical Trials

Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

13th February 2019
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
Manufacturing

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

13th February 2019
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Drug Development

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

13th February 2019
U.S. FDA Approves DARZALEX Split-Dosing Regimen
FDA Approvals

U.S. FDA Approves DARZALEX Split-Dosing Regimen

13th February 2019
Next Post
Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology

Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology

Latest News

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet
Manufacturing

Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet

20th February 2019
Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Clinical Trials

Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

13th February 2019
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
Manufacturing

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

13th February 2019
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Drug Development

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

13th February 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Market Moves OLD
  • Manufacturing
  • News
  • Events & Conferences

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Download Media Pack

Close

x
No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In